
News|Articles|February 3, 2025
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
Author(s)PurpleLab
A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Trending on Applied Clinical Trials Online
1
FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development
2
Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches
3
Global by Design: What 2026 Means for Sites, Sponsors, and Trial Operations
4
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
5